Additional file 4: Figure S4. Adjusted risk difference and adjusted odds ratio (OR) for treatment failure for each risk factor from a conservative imputation model. In this model, we included only patients with confirmed dates for both SARS-CoV-2 positive test and mAb administration. Risk differences were calculated via Firth's bias-reduced multiple regression logistic regression. Adjusted ORs and 95% confidence intervals (95% CI) were computed by penalized profile likelihood
BACKGROUND: In a randomized, placebo-controlled, clinical trial, bamlanivimab, a SARS-CoV-2-neutrali...
Model additionally includes time from preimmunization to serology (i.e., months since last infection...
Model includes type of vaccine and timing of vaccinations between dose 1 and dose 2. (PDF)</p
Additional file 3: Figure S3. Adjusted risk difference and adjusted odds ratio (OR) for treatment fa...
Additional file 5: Table S1. Medications and conditions used to stratify Mild versus Moderate/Severe...
Additional file 2: Figure S2. Cumulative incidence of hazard for hospitalization by immunocompromise...
Objective: To test the hypothesis that the Monoclonal Antibody Screening Score performs consistently...
The rate of prescription of drugs across the inpatient A) The measured effect of COVID-19 incidence ...
Background: Monoclonal antibodies represent one option for treatment of COVID-19 early after infecti...
<p>All models were adjusted for study site. Baseline CD4 cell count and adherence were not significa...
Background: The aim of this secondary analysis of the TESEO cohort is to identify, early in the cour...
Logistic regression modelling evaluating risk factors related to the severity of clinical manifestat...
BackgroundThe aim of this secondary analysis of the TESEO cohort is to identify, early in the course...
Note: The table reports results obtained by estimating the baseline specification of our model using...
Objectives To evaluate the benefits of vaccination on the case fatality rate (CFR) for COVID-19 infe...
BACKGROUND: In a randomized, placebo-controlled, clinical trial, bamlanivimab, a SARS-CoV-2-neutrali...
Model additionally includes time from preimmunization to serology (i.e., months since last infection...
Model includes type of vaccine and timing of vaccinations between dose 1 and dose 2. (PDF)</p
Additional file 3: Figure S3. Adjusted risk difference and adjusted odds ratio (OR) for treatment fa...
Additional file 5: Table S1. Medications and conditions used to stratify Mild versus Moderate/Severe...
Additional file 2: Figure S2. Cumulative incidence of hazard for hospitalization by immunocompromise...
Objective: To test the hypothesis that the Monoclonal Antibody Screening Score performs consistently...
The rate of prescription of drugs across the inpatient A) The measured effect of COVID-19 incidence ...
Background: Monoclonal antibodies represent one option for treatment of COVID-19 early after infecti...
<p>All models were adjusted for study site. Baseline CD4 cell count and adherence were not significa...
Background: The aim of this secondary analysis of the TESEO cohort is to identify, early in the cour...
Logistic regression modelling evaluating risk factors related to the severity of clinical manifestat...
BackgroundThe aim of this secondary analysis of the TESEO cohort is to identify, early in the course...
Note: The table reports results obtained by estimating the baseline specification of our model using...
Objectives To evaluate the benefits of vaccination on the case fatality rate (CFR) for COVID-19 infe...
BACKGROUND: In a randomized, placebo-controlled, clinical trial, bamlanivimab, a SARS-CoV-2-neutrali...
Model additionally includes time from preimmunization to serology (i.e., months since last infection...
Model includes type of vaccine and timing of vaccinations between dose 1 and dose 2. (PDF)</p